bicalutamide sandoz 150 mg film-coat. tabl.
sandoz sa-nv - bicalutamide 150 mg - film-coated tablet - 150 mg - bicalutamide 150 mg - bicalutamide
bicalutamide teva 50 mg film-coat. tabl.
teva pharma belgium sa-nv - bicalutamide 50 mg - film-coated tablet - 50 mg - bicalutamide 50 mg - bicalutamide
bicalutamide tablet
remedyrepack inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see us
dom-bicalutamide tablet
dominion pharmacal - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents
mylan-bicalutamide tablet
mylan pharmaceuticals ulc - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents
jamp-bicalutamide tablet
jamp pharma corporation - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents
med-bicalutamide tablet
generic medical partners inc - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents
bicalutamide 150mg tablets
a a h pharmaceuticals ltd - bicalutamide - oral tablet - 150mg
bicalutamide 150mg tablets
alliance healthcare (distribution) ltd - bicalutamide - oral tablet - 150mg
bicalutamide 150mg tablets
pliva pharma ltd - bicalutamide - oral tablet - 150mg